Surveying The Biosimilar Battlefield
The biosimilar market has been of particular interest to us in light of the high expectations set for Samsung Biologics Co., Ltd (207940 KS) and...
838 Views
Celltrion Has Potential Manufacturing Headaches
A Form 483 from the USFDA (attached) that criticizes aspects of Celltrion Inc (068270 KS)'s manufacturing facility in Incheon has surfaced in the...
626 Views
The Disconnect Is Growing
Celltrion Inc (068270 KS) 's Inflectra, a biosimilar to Johnson & Johnson (JNJ US) 's Remicade, had little impact on the critical U.S. market...
706 Views
Celltrion Healthcare IPO - Summary on Last Week's IPO Roadshow in HK & Singapore
Celltrion Healthcare just completed the pre-IPO roadshows in Hong Kong and Singapore last week. The company officials met about 15 institutional...
426 Views
Recent Developments Not Encouraging
This Insight provides an update on developments in the US market related to biosimilars, and are of great significance to Celltrion Inc (068270...
315 Views